{"DataElement":{"publicId":"7463251","version":"1","preferredName":"Procedure Domain Cancer Therapeutic Procedure Administered Type","preferredDefinition":"Indication of the type of anti-cancer therapy given to the patient.","longName":"PR_PRCAT_ANTICATX","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7463247","version":"1","preferredName":"Procedure Domain Cancer Therapeutic Procedure Administered","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure._Any intervention for management of a malignant neoplasm._The act of having given something (e.g., a medication or test).","longName":"6407261v1.0:7464062v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"6407261","version":"1","preferredName":"Procedure Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure.","longName":"C102700","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procedure Domain","conceptCode":"C102700","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"73F3626C-19A3-3896-E053-F662850A4518","latestVersionIndicator":"Yes","beginDate":"2018-08-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-21","modifiedBy":"ONEDATA","dateModified":"2018-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7464062","version":"1","preferredName":"Cancer Therapeutic Procedure Administered","preferredDefinition":"Any intervention for management of a malignant neoplasm.:The act of having given something (e.g., a medication or test).","longName":"C16212:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cancer Therapeutic Procedure","conceptCode":"C16212","definition":"Any intervention for management of a malignant neoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1945CB5-8C84-5064-E053-4EBD850AF60F","latestVersionIndicator":"Yes","beginDate":"2020-10-13","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-13","modifiedBy":"ONEDATA","dateModified":"2020-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1426DC7-8EAF-2E79-E053-4EBD850A40E8","latestVersionIndicator":"Yes","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"SPRINGERL","dateModified":"2020-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7463244","version":"1","preferredName":"Therapeutic Procedure Administered Type","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._The act of having given something (e.g., a medication or test)._Something distinguishable as an identifiable class based on common qualities.","longName":"7463244v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"350","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Radiation Therapy","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2567129","version":"1","preferredName":"Radiation Therapy","longName":"2567129","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D346-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-21","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-10-21","modifiedBy":"KUMMEROA","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B14199BA-0B8D-4A45-E053-4EBD850AF4EA","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"ONEDATA","dateModified":"2020-10-09","deletedIndicator":"No"},{"value":"Surgery","valueDescription":"Surgical Procedure","ValueMeaning":{"publicId":"3440172","version":"1","preferredName":"Surgical Procedure","longName":"3440172","preferredDefinition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Surgical Procedure","conceptCode":"C15329","definition":"A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE12571D-0867-9ACA-E040-BB89AD4324C1","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-19","modifiedBy":"KUMMEROA","dateModified":"2024-02-22","changeDescription":"Added OBIB alternate name and identifier DW 03-21-2019","administrativeNotes":"2023.1.20 Alt VM added per ticket request CADSR0001943. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B14199BA-0B97-4A45-E053-4EBD850AF4EA","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"ONEDATA","dateModified":"2020-10-09","deletedIndicator":"No"},{"value":"Stem Cell Transplant","valueDescription":"Hematopoietic Cell Transplantation","ValueMeaning":{"publicId":"4395931","version":"1","preferredName":"Hematopoietic Cell Transplantation","longName":"4395931","preferredDefinition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEBB1E93-3F07-E882-E040-BB89AD431336","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-07-21","modifiedBy":"MMADDINENI","dateModified":"2024-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B14199BA-0BA1-4A45-E053-4EBD850AF4EA","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"ONEDATA","dateModified":"2020-10-09","deletedIndicator":"No"},{"value":"Chemotherapy","valueDescription":"Chemotherapy","ValueMeaning":{"publicId":"5102333","version":"1","preferredName":"Chemotherapy","longName":"5102333","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-0232-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B14199BA-0BAB-4A45-E053-4EBD850AF4EA","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"ONEDATA","dateModified":"2020-10-09","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"3126125","version":"1","preferredName":"Other","longName":"3126125","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D01180C-814A-B8B4-E040-BB89AD432507","latestVersionIndicator":"Yes","beginDate":"2010-08-04","endDate":null,"createdBy":"MAESKEB","dateCreated":"2010-08-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-07","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/03/2015.","administrativeNotes":"2023.3.7 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B145F7AF-38E4-3FA9-E053-4EBD850AA6D2","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"ONEDATA","dateModified":"2020-10-09","deletedIndicator":"No"},{"value":"Primary","valueDescription":null,"ValueMeaning":{"publicId":"2590540","version":"1","preferredName":"Primary","longName":"2590540","preferredDefinition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"27C9E68B-FDD6-24D2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-24","modifiedBy":"CLOHNES","dateModified":"2022-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8AEBB63-BCBD-2015-E053-731AD00A33B4","beginDate":"2022-09-14","endDate":null,"createdBy":"LISU","dateCreated":"2022-09-14","modifiedBy":"LISU","dateModified":"2022-09-14","deletedIndicator":"No"},{"value":"Metastatic","valueDescription":null,"ValueMeaning":{"publicId":"5189148","version":"1","preferredName":"Metastatic","longName":"5189148","preferredDefinition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic","conceptCode":"C14174","definition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E972B2B-1743-F356-E050-BB89AD4360B6","latestVersionIndicator":"Yes","beginDate":"2016-03-21","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-03-21","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E8AEBB63-BCBE-2015-E053-731AD00A33B4","beginDate":"2022-09-14","endDate":null,"createdBy":"LISU","dateCreated":"2022-09-14","modifiedBy":"LISU","dateModified":"2022-09-14","deletedIndicator":"No"},{"value":"Allogeneic Stem Cell Transplant","valueDescription":null,"ValueMeaning":{"publicId":"2688157","version":"1","preferredName":"Allogeneic Hematopoietic Stem Cell Transplantation","longName":"2688157","preferredDefinition":"A clinical treatment in which HSC capable of reconstituting the immune system and blood production (hematopoiesis) are transferred from one genetically dissimilar individual to another. The donor and recipient may or may not be related. 2005","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Allogeneic Hematopoietic Stem Cell Transplantation","conceptCode":"C46089","definition":"A clinical treatment in which hematopoietic stem cells (HSCs) are transferred from one genetically dissimilar individual to another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C02704A-A3F4-6131-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-08","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-10-08","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8AA92ED-4EB2-58CE-E053-731AD00A635B","beginDate":"2023-04-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-06","modifiedBy":"KUMMEROA","dateModified":"2023-04-06","deletedIndicator":"No"},{"value":"Autologous Stem Cell Transplant","valueDescription":null,"ValueMeaning":{"publicId":"2688156","version":"1","preferredName":"Autologous Stem Cell Transplantation","longName":"2688156","preferredDefinition":"The transference of stem cells within the same individual.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autologous Hematopoietic Stem Cell Transplantation","conceptCode":"C16039","definition":"Stem cell transfer or transplantation in which the patient is their own donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C02704A-A3CF-6131-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-08","endDate":null,"createdBy":"JOSHUAT","dateCreated":"2007-10-08","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8AA92ED-4EB3-58CE-E053-731AD00A635B","beginDate":"2023-04-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-06","modifiedBy":"KUMMEROA","dateModified":"2023-04-06","deletedIndicator":"No"},{"value":"Brentuximab Vedotin","valueDescription":null,"ValueMeaning":{"publicId":"3228385","version":"1","preferredName":"Brentuximab Vedotin","longName":"3228385","preferredDefinition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16046E6-D6A0-1B8D-E040-BB89AD434ADA","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"KUMMEROA","dateModified":"2023-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8AA92ED-4EB4-58CE-E053-731AD00A635B","beginDate":"2023-04-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-06","modifiedBy":"KUMMEROA","dateModified":"2023-04-06","deletedIndicator":"No"},{"value":"Immunotherapy","valueDescription":null,"ValueMeaning":{"publicId":"5102332","version":"1","preferredName":"Immunotherapy","longName":"5102332","preferredDefinition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-01FA-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F8AA92ED-4EB5-58CE-E053-731AD00A635B","beginDate":"2023-04-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-04-06","modifiedBy":"KUMMEROA","dateModified":"2023-04-06","deletedIndicator":"No"},{"value":"Immunotherapy/Cellular therapy","valueDescription":null,"ValueMeaning":{"publicId":"14103247","version":"1","preferredName":"Immunotherapy And/Or Cellular Therapy","longName":"14103247v1.00","preferredDefinition":"Therapy designed to induce changes in a patient's immune status in order to treat disease._Used to indicate that either or both of two items or options may be valid._Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cellular Therapy","conceptCode":"C70601","definition":"Utilization of specific cells, modified or not, for treatment of diseases. Donor lymphocyte infusion is a type of cellular therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"00DB1FFE-07C2-4080-E063-731AD00AFCA3","latestVersionIndicator":"Yes","beginDate":"2023-07-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-19","modifiedBy":"KUMMEROA","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"00DB1FFE-07C3-4080-E063-731AD00AFCA3","beginDate":"2023-07-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-07-19","modifiedBy":"KUMMEROA","dateModified":"2023-07-19","deletedIndicator":"No"},{"value":"MIBG therapy","valueDescription":null,"ValueMeaning":{"publicId":"5784004","version":"1","preferredName":"Iobenguane Therapeutic Procedure","longName":"5784004","preferredDefinition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.: An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iobenguane","conceptCode":"C87757","definition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E29372D-CBCC-2586-E053-F662850AB0FA","latestVersionIndicator":"Yes","beginDate":"2017-04-27","endDate":null,"createdBy":"DAVISJ","dateCreated":"2017-04-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA4E4B1-C08C-0F3C-E063-731AD00AD869","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Anti-GD2 therapy","valueDescription":null,"ValueMeaning":{"publicId":"14722866","version":"1","preferredName":"Anti-GD2 Therapy","longName":"14722866v1.00","preferredDefinition":"Any therapy that specifically targets the tumor-associated antigen (TAA) disialoganglioside GD2.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-GD2 Therapy","conceptCode":"C174558","definition":"Any therapy that specifically targets the tumor-associated antigen (TAA) disialoganglioside GD2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FA4E4B1-C088-0F3C-E063-731AD00AD869","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA4E4B1-C08D-0F3C-E063-731AD00AD869","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"ALK inhibitor","valueDescription":null,"ValueMeaning":{"publicId":"6010235","version":"1","preferredName":"ALK Inhibitor","longName":"6010235","preferredDefinition":"Any agent that inhibits the activity of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ALK Inhibitor","conceptCode":"C141136","definition":"Any agent that inhibits the activity of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C5067E7-F1FC-4D7F-E053-F662850A1EF2","latestVersionIndicator":"Yes","beginDate":"2017-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA4E4B1-C08E-0F3C-E063-731AD00AD869","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Single stem cell transplant","valueDescription":null,"ValueMeaning":{"publicId":"14722867","version":"1","preferredName":"Autologous Stem Cell Transplantation","longName":"14722867v1.00","preferredDefinition":"Stem cell transfer or transplantation in which the patient is their own donor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autologous Stem Cell Transplantation","conceptCode":"C201465","definition":"Stem cell transfer or transplantation in which the patient is their own donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FA4E4B1-C089-0F3C-E063-731AD00AD869","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA4E4B1-C08F-0F3C-E063-731AD00AD869","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Tandem stem cell transplant","valueDescription":null,"ValueMeaning":{"publicId":"6834272","version":"1","preferredName":"Tandem Hematopoietic Stem Cell Transplantation","longName":"6834272","preferredDefinition":"A type of autologous stem cell transplant, during which the patient receives two sequential courses of high-dose chemotherapy with stem cell transplant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tandem Hematopoietic Stem Cell Transplantation","conceptCode":"C116469","definition":"A type of autologous stem cell transplant, during which the patient receives two sequential courses of high-dose chemotherapy with stem cell transplant.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9D9613-0B1D-0170-E053-F662850ADBE1","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"STARGELM","dateCreated":"2019-07-26","modifiedBy":"ONEDATA","dateModified":"2019-07-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA4E4B1-C090-0F3C-E063-731AD00AD869","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Chemoimmunotherapy","valueDescription":null,"ValueMeaning":{"publicId":"6834270","version":"1","preferredName":"Chemoimmunotherapy","longName":"6834270","preferredDefinition":"Chemotherapy combined with immunotherapy. Chemotherapy uses different drugs to kill or slow the growth of cancer cells; immunotherapy uses treatments to stimulate or restore the ability of the immune system to fight cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemoimmunotherapy","conceptCode":"C94251","definition":"Chemotherapy combined with immunotherapy. Chemotherapy uses different drugs to kill or slow the growth of cancer cells; immunotherapy uses treatments to stimulate or restore the ability of the immune system to fight cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E9D9613-0AF7-0170-E053-F662850ADBE1","latestVersionIndicator":"Yes","beginDate":"2019-07-26","endDate":null,"createdBy":"STARGELM","dateCreated":"2019-07-26","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA4E4B1-C091-0F3C-E063-731AD00AD869","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Anti-GD2 antibody","valueDescription":null,"ValueMeaning":{"publicId":"14722868","version":"1","preferredName":"Anti-GD2 Monoclonal Antibody","longName":"14722868v1.00","preferredDefinition":"Any monoclonal antibody that is directed against the GD2 (GD-2) antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-GD2 Monoclonal Antibody","conceptCode":"C155653","definition":"Any monoclonal antibody that is directed against the GD2 (GD-2) antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FA4E4B1-C08A-0F3C-E063-731AD00AD869","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA4E4B1-C092-0F3C-E063-731AD00AD869","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"Anti-GD2 Vaccine","valueDescription":null,"ValueMeaning":{"publicId":"14722869","version":"1","preferredName":"GD2-KLH Vaccine","longName":"14722869v1.00","preferredDefinition":"A cancer vaccine containing an epitope of glycosphingolipid GD2 conjugated with the immunostimulant keyhole limpet hemocyanin (KLH), with potential antineoplastic activity.  The disialoganglioside GD2 is a tumor-associated antigen expressed on the surface of several cancers, including neuroblastoma medulloblastomas, astrocytomas, melanomas, small-cell lung cancer, osteosarcomas, and other soft tissue sarcomas. Vaccination with GD2-KLH vaccine may elicit antibody production against cells expressing GD2 ganglioside, thereby reducing tumor cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GD2-KLH Vaccine","conceptCode":"C2400","definition":"A cancer vaccine containing an epitope of glycosphingolipid GD2 conjugated with the immunostimulant keyhole limpet hemocyanin (KLH), with potential antineoplastic activity.  The disialoganglioside GD2 is a tumor-associated antigen expressed on the surface of several cancers, including neuroblastoma medulloblastomas, astrocytomas, melanomas, small-cell lung cancer, osteosarcomas, and other soft tissue sarcomas. Vaccination with GD2-KLH vaccine may elicit antibody production against cells expressing GD2 ganglioside, thereby reducing tumor cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FA4E4B1-C08B-0F3C-E063-731AD00AD869","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0FA4E4B1-C093-0F3C-E063-731AD00AD869","beginDate":"2024-01-23","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-23","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","deletedIndicator":"No"},{"value":"DFMO +/- other agents","valueDescription":null,"ValueMeaning":{"publicId":"14761167","version":"1","preferredName":"Eflornithine With Or Without Other Agent","longName":"14761167v1.00","preferredDefinition":"A difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. (NCI04)_Used to indicate the presence of something or someone._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Used to indicate the absence or lack of something or someone._Different than the one(s) previously specified or mentioned._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eflornithine","conceptCode":"C226","definition":"A difluoromethylated ornithine compound with antineoplastic activity.  Eflornithine irreversibly inhibits ornithine decarboxylase, an enzyme required for polyamine biosynthesis, thereby inhibiting the formation and proliferation of tumor cells. Polyamines are involved in nucleosome oligomerization and DNA conformation, creating a chromatin environment that stimulates neoplastic transformation of cells. This agent has been shown to induce apoptosis in leiomyoma cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"117157BD-8C60-466A-E063-731AD00A2AA6","latestVersionIndicator":"Yes","beginDate":"2024-02-15","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-02-15","modifiedBy":"MMADDINENI","dateModified":"2024-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"117157BD-8C61-466A-E063-731AD00A2AA6","beginDate":"2024-02-15","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-02-15","modifiedBy":"MMADDINENI","dateModified":"2024-02-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7463243","version":"1","preferredName":"Therapeutic Procedure Administered Type","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.:The act of having given something (e.g., a medication or test).:Something distinguishable as an identifiable class based on common qualities.","longName":"C49236:C25382:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B145F7AF-38BC-3FA9-E053-4EBD850AA6D2","latestVersionIndicator":"Yes","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"ONEDATA","dateModified":"2020-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B145F7AF-38CD-3FA9-E053-4EBD850AA6D2","latestVersionIndicator":"Yes","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"MMADDINENI","dateModified":"2024-02-15","changeDescription":null,"administrativeNotes":"2023.7.19 PV added per ticket request CADSR0002626. ak 2023.4.6 PVs added per ticket request CADSR0002244. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"PR_PRCAT_SURG","type":"COG Form Element","context":"COG"},{"name":"PR_PRCAT_ANTICATX","type":"COG Form Element","context":"COG"},{"name":"PR_PRCAT","type":"COG Form Element","context":"COG"},{"name":"PR_PRCAT_ALTNTX","type":"COG Form Element","context":"COG"}],"ReferenceDocuments":[{"name":"Type of anti-cancer therapy:","type":"Preferred Question Text","description":"Type of anti-cancer therapy:","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Type(s) of anti-cancer therapy:","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"If Yes, type(s) of anti-cancer therapy the patient received:","url":null,"context":"COG"},{"name":"COG CRF TEXT3","type":"Alternate Question Text","description":"If yes, Type of surgery performed","url":null,"context":"COG"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Type(s) of anti-cancer therapy the patient received","url":null,"context":"COG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Type(s) of anti-cancer therapy that the patient received","url":null,"context":"COG"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"Indicate the type(s) of anti-cancer therapy that the patient received","url":null,"context":"COG"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"If Plan to receive alternate therapy, specify:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B141A65F-988E-4A49-E053-4EBD850A4E54","latestVersionIndicator":"Yes","beginDate":"2020-10-09","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-10-09","modifiedBy":"MMADDINENI","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":"2023.7.26 AQTs added per ticket request CADSR0002655. ak 2023.7.19 AQT added per ticket request CADSR0002626. ak","unresolvedIssues":null,"deletedIndicator":"No"}}